Skip to main content
. 2021 Jul 2;8:705487. doi: 10.3389/fcvm.2021.705487

Table 1.

Baseline characteristics of the study population.

Total STEMI (n = 129) LVEF <55% (n = 85) LVEF ≥55% (n = 44) P-value
Age, years 55 (48–63) 52 (46–63) 56 (50–62) 0.26
Male, n (%) 112 (87) 71 (84) 41 (93) 0.12
Body mass index, kg/m2 25.4 (23.8–27.7) 25.5 (23.8–27.9) 25.4 (23.2–27.1) 0.52
Hypertension, n (%) 64 (50) 44 (52) 20 (46) 0.50
Hyperlipidemia, n (%) 93 (72) 61 (72) 32 (73) 0.91
Diabetes mellitus, n (%) 40 (31) 25 (29) 15 (34) 0.59
Smoker, n (%) 92 (71) 57 (67) 35 (80) 0.14
Ischemia time, h 5.0 (3.0–7.8) 5.0 (3.0–7.3) 5.0 (3.0–8.0) 0.81
TIMI flow pre-PCI, n (%) 0.02
   0 71 (55) 54 (63) 17 (39)
   1 10 (8) 6 (7) 4 (9)
   2 15 (12) 10 (12) 5 (11)
   3 33 (25) 15 (18) 18 (41)
TIMI flow post-PCI, n (%) 1.00
   0 2 (1) 1 (1) 1 (2)
   1 0 (0) 0 (0) 0 (0)
   2 1 (1) 1 (1) 0 (0)
   3 126 (98) 83 (98) 43 (98)
Number of diseased vessels 0.63
   1 49 (38) 32 (38) 17 (39)
   2 47 (36) 31 (36) 16 (36)
   3 33 (26) 22 (26) 11 (25)
Admission creatinine, μmol/L 74.6 (65.2–85.2) 74.8 (65.0–86.0) 73.1 (66.2–84.4) 0.88
Peak cTnI, ng/mL 27.0 (9.5–53.3) 33.5 (18.2–60.1) 13.5 (6.6–31.6) 0.001
Time of peak cTnI, h 20 (14–27) 21 (15–27) 19 (12–27) 0.38
Peak NT-proBNP, pg/mL 1,364.5 (729.1–2,889.1) 1,666.1 (915.9–3,215.3) 914.7 (404.7–2,072.2) 0.001
Time of peak NT-proBNP, h 29 (22–42) 32 (24–49) 26 (19–32) 0.004

PCI, percutaneous coronary intervention; cTnI, cardiac troponin I; NT-proBNP, N terminal pro B type natriuretic peptide.